Comment from Novartis Pharmaceuticals Corporation

Summary: Novartis Pharmaceuticals Corporation submitted comments providing a specific example of a drug candidate (clofazimine) for repurposing to address unmet medical needs. They highlight the barriers to formal approval for clofazimine despite existing scientific support and real-world use for various infections.